Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG

NeuroImage

Volumn 52, Issue 2, 2010, Pages 488-496

  Shin, Jonghan ^a,b   Lee, Sang Yoon ^a   Kim, Seog Ju ^a   Kim, So Hee ^a   Cho, Seong Jin ^a   Kim, Young Bo ^a  

^a Gachon University College of Medicine   (South Korea)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer; Amyloid; Metabolism; Neuropathology; Positron emission tomography; Tau

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL) (METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; AMYLOID; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; TRACER; UNCLASSIFIED DRUG; 2-(1-(6-((2-FLUOROETHYL)(METHYL)AMINO)-2-NAPHTHYL)ETHYLIDENE)MALONONITRILE; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; GLUCOSE; NITRILE; RADIOPHARMACEUTICAL AGENT; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG BINDING; ENTORHINAL CORTEX; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; MALE; NEUROFIBRILLARY TANGLE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE; VISUAL CORTEX; AMYLOID PLAQUE; BRAIN; BRAIN MAPPING; CASE CONTROL STUDY; DIAGNOSTIC USE; METABOLISM; PROCEDURES; SCINTISCANNING; SIGNAL PROCESSING;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; NITRILES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENILE PLAQUES; SIGNAL PROCESSING, COMPUTER-ASSISTED; THIAZOLES; PLAQUE, AMYLOID;

EID: 77955707891     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2010.04.013     Document Type: Article

References (68)

1. Aalto S., Scheinin N.M., Kemppainen N.M., Någren K., Kailajärvi M., Leinonen M., Scheinin M., Rinne J.O. Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [(11)C]PIB uptake using 30-min scanning data. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1651-1660.
2. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., Cole G.M., Small G.W., Huang S.C., Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 2001, 21:RC189.
3. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 2002, 159:738-745.
4. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1991, 1:103-116.
5. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
6. Benson D.F., Kuhl D.E., Hawkins R.A., Phelps M.E., Cummings J.L., Tsai S.Y. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch. Neurol. 1983, 40:711-714.
7. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
8. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
9. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
10. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005, 25:7709-7717.
11. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 2008, 1124:1-38.
12. Cairns N.J., Bigio E.H., Mackenzie I.R., Neumann M., Lee V.M., Hatanpaa K.J., White C.L., Schneider J.A., Grinberg L.T., Halliday G., Duyckaerts C., Lowe J.S., Holm I.E., Tolnay M., Okamoto K., Yokoo H., Murayama S., Woulfe J., Munoz D.G., Dickson D.W., Ince P.G., Trojanowski J.Q., Mann D.M. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007, 114:5-22. Consortium for Frontotemporal Lobar Degeneration.
13. Cohen N.J., Eichenbaum H. Memory, amnesia, and the hippocampal system 1993, The MIT Press, Cambridge, MA.
14. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., Bobinski M., Caraos C., Lesbre P., Schlyer D., Poirier J., Reisberg B., Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10966-10971.
15. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., Hotton G., Cutler D., Fox N., Kennedy A., Rossor M., Brooks D.J. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
16. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
17. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
18. Furukawa K., Okamura N., Tashiro M., Waragai M., Furumoto S., Iwata R., Yanai K., Kudo Y., Arai H. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET. J. Neurol 2010, 257:721-727.
19. Gearing M., Rebeck G.W., Hyman B.T., Tigges J., Mirra S.S. Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9382-9386.
20. Giannakopoulos P., Hof P.R., Bouras C. Selective vulnerability of neocortical association areas in Alzheimer's disease. Microsc. Res. Tech. 1998, 43:16-23.
21. Greco S.J., Sarkar S., Johnston J.M., Tezapsidis N. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem. Biophys. Res. Commun. 2009, 380:98-104.
22. Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 2003, 60:729-736.
23. Hardy J.A., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
24. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis. Assoc. Disord. 1995, 9:6-16.
25. Kemppainen N.M., Aalto S., Wilson I.A., Någren K., Helin S., Brück A., Oikonen V., Kailajärvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006, 67:1575-1580.
26. Kepe V., Huang S.C., Small G.W., Satyamurthy N., Barrio J.R. Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. Methods Enzymol. 2006, 412:144-160.
27. Kim E.J., Cho S.S., Jeong Y., Park K.C., Kang S.J., Kang E., Kim S.E., Lee K.H., Na D.L. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 2005, 128:1790-1801.
28. Klunk W.E., Wang Y., Huang G.F., Debnath M.L., Holt D.P., Shao L., Hamilton R.L., Ikonomovic M.D., DeKosky S.T., Mathis C.A. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 2003, 23:2086-2092.
29. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
30. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K., Arai H. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 2007, 48:553-561.
31. Kumar A., Schapiro M.B., Grady C., Haxby J.V., Wagner E., Salerno J.A., Friedland R.P., Rapoport S.I. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 1991, 4:35-46.
32. Lange K.L., Bondi M.W., Salmon D.P., Galasko D., Delis D.C., Thomas R.G., Thal L.J. Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. J. Int. Neuropsychol. Soc. 2002, 8:943-955.
33. Lewis D.A., Campbell M.J., Terry R.D., Morrison J.H. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices. J. Neurosci. 1987, 7:1799-1808.
34. 18F]FDDNP) ready for animal and human administration. Mol. Imaging Biol. 2007, 9:6-16.
35. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., Meltzer C.C., Schimmel K., Tsopelas N.D., DeKosky S.T., Price J.C. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. 2005, 46:1959-1972.
36. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2003, 46:2740-2754.
37. McCarthy T.J. The role of imaging in drug development. Q. J. Nucl. Med. Mol. Imaging 2009, 53:382-386.
38. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
39. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 1997, 42:85-94.
40. Mitchell T.W., Mufson E.J., Schneider J.A., Cochran E.J., Nissanov J., Han L.Y., Bienias J.L., Lee V.M., Trojanowski J.Q., Bennett D.A., Arnold S.E. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann. Neurol. 2002, 51:182-189.
41. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
42. Mosconi L., Tsui W.H., Rusinek H., De Santi S., Li Y., Wang G.J., Pupi A., Fowler J., de Leon M.J. Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1467-1479.
43. Noda A., Murakami Y., Nishiyama S., Fukumoto D., Miyoshi S., Tsukada H., Nishimura S. Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. Synapse 2008, 62:472-475.
44. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr. Opin. Neurol. 2007, 20:398-402.
45. Padgett H.C., Schmidt D.G., Luxen A., Bida G.T., Satyamurthy N., Barrio J.R. Computer-controlled radiochemical synthesis: a chemistry process control unit for the automated production of radiochemicals. Int. J. Rad. Appl. Instrum. A 1989, 40:433-445.
46. Protas H.D., Huang S.C., Kepe V., Hayashi K., Klunder A., Braskie M.N., Ercoli L., Bookheimer S., Thompson P.M., Small G.W., Barrio J.R. FDDNP binding using MR derived cortical surface maps. Neuroimage 2009, 49:240-248.
47. Rabinovici G.D., Furst A.J., O'Neil J.P., Racine C.A., Mormino E.C., Baker S.L., Chetty S., Patel P., Pagliaro T.A., Klunk W.E., Mathis C.A., Rosen H.J., Miller B.L., Jagust W.J. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68:1205-1212.
48. Robichaud A.J., Rotella D.P. Alzheimer's Disease: A Light at the End of the Tunnel?. Drug Dev. Res. 2009, 70:57-59.
49. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
50. Seabrook G.R., Ray W.J., Shearman M., Hutton M. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol. Interv. 2007, 7:261-270.
51. Shin J., Kim D., Bianchi R., Wong R.K., Shin H.S. Genetic dissection of theta rhythm heterogeneity in mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18165-18170.
52. Shin J., Lee S.Y., Kim S.H., Kim Y.B., Cho S.J. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 2008, 43:236-244.
53. Shin J., Gireesh G., Kim S.W., Kim D.S., Lee S., Kim Y.S., Watanabe M., Shin H.S. Phospholipase C b4 in the medial septum controls cholinergic theta oscillations and anxiety behaviors. J. Neurosci. 2009, 29:15375-15385.
54. Shin J., Lee S.Y. 2-(1-{6-[(2-[Fluorine-18]fluoroethyl)(methyl) amino]-2-naphthyl}ethylidene)malononitrile (FDDNP) positron emission tomography patterns in nondemented populations. Am. J. Geriatr. Psychiatry 2010, 18:187.
55. Shin, J., in press. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease. Int. J. Geriatr. Psychiatry.
56. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2002, 10:24-35.
57. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
58. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006, 355:2652-2663.
59. Small G.W., Kepe V., Barrio J.R. Seeing is believing: neuroimaging adds to our understanding of cerebral pathology. Curr. Opin. Psychiatry 2006, 19:564-569.
60. Souvatzoglou M., Ziegler S.I., Martinez M.J., Busch R., Dzewas G., Schwaiger M., Bengel F. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:405-412.
61. Strack T. Imaging as a tool in drug development. Drugs Today (Barc) 2007, 43:725-736.
62. Suh Y.H., Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 2002, 54:469-525.
63. Talairach J., Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. Three-Dimensional Proportional System: An Approach to Cerebral Imaging 1988, Thieme, New York.
64. Thompson P.W., Ye L., Morgenstern J.L., Sue L., Beach T.G., Judd D.J., Shipley N.J., Libri V., Lockhart A. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem. 2009, 109:623-630.
65. Tolboom N., van der Flier W.M., Yaqub M., Boellaard R., Verwey N.A., Blankenstein M.A., Windhorst A.D., Scheltens P., Lammertsma A.A., van Berckel B.N. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J. Nucl. Med. 2009, 50:1464-1470.
66. Wong K.P., Wardak M., Shao W., Dahlbom M., Kepe V., Liu J., Satyamurthy N., Small G.W., Barrio J.R., Huang S.C. Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:575-588.
67. Yakushev I., Hammers A., Fellgiebel A., Schmidtmann I., Scheurich A., Buchholz H.G., Peters J., Bartenstein P., Lieb K., Schreckenberger M. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 2009, 44:43-50.
68. Ziolko S.K., Weissfeld L.A., Klunk W.E., Mathis C.A., Hoge J.A., Lopresti B.J., DeKosky S.T., Price J.C. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006, 33:94-102.